Todos Medical Enters Into Cross-Distribution Agreement With L1 Systems for Ventilators and COVID Testing
MAY 26, 2020 9:19AM EDT
Todos gains distribution rights to LifeCan Ventilator in Brazil, Mexico & Latin America
Ventilator access will help prospective government and NGO procurers of COVID-related medical products reduce need for additional suppliers to address critical health needs
L1 distribution network will provide untapped market access for Todos’ tests
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a cross-distribution agreement with L1 Systems, Ltd., a wholly-owned subsidiary of Medigus, Ltd. (NASDAQ:MDGS) (TASE:MDGS), for the distribution of COVID-19 related products, including ventilators. Todos is making available to L1 its comprehensive suite of testing solutions that covers best-in-class RNA extraction equipment, RNA extraction reagents, qPCR reagents, Digital PCR reagents and US-validated SARS-CoV-2 rapid point-of-care antibody test kits for non-exclusive distribution. L1 is making available to Todos the LifeCan ventilators, manufactured by Elbit Systems, for non-exclusive distribution in Mexico and Latin America, including Brazil. This agreement strengthens both companies’ core offerings and allows each company to focus on markets where they are developing reliable sales channels.
“Given that Todos’ team has been focused recently on penetrating the Latin American market, where a marked uptick in COVID-19 infections has led to a significantly increased need for COVID-19 testing and critical care treatment options, we believe gaining access to a high quality medical grade ventilator will further bring attention to Todos’ test offering due to the severe global shortage in ventilators,” said Gerald Commissiong, President & CEO of Todos Medical.
Mr. Commissiong continued, “When a country is dealing with a pandemic crisis such as COVID-19, getting trusted sources of medical supplies from which a procurement agent can acquire multiple lines of needed products substantially increases a supplier’s profile within that procurement agency, and provides the supplier an opportunity to expose the procurer to the rest of its portfolio in a more comprehensive way. Ventilators are often the difference between life and death when treating patients, and we believe getting access to a nimble and tailored product such as LifeCan – a simple, high-quality product that was designed in Israel to respond to many of the recent concerns with the established medical ventilator designs – gives Todos a significant edge when competing for contracts from foreign governments, hospital systems and others users of healthcare products and services. As we continue to build our international import/export division, this agreement positions Todos to stand out from other companies competing for contracts in key markets.”
About the SARS-CoV-2 Coronavirus (COVID-19)
Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is the disease caused by SARS-CoV-2.
About Medigus, Ltd.
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the company’s advanced technology, please visit www.medigus.com.
About Todos Medical Ltd.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020.
Todos recently entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements with multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed Corona Diagnostics, LLC, a strategic collaboration with Emerald Organic Products, Inc. (OTC: EMOR), to support telemedicine and virtual pharmacy aspects of the commercialization of its COVID-19 return to work testing programs in the US.
For more information, please visit https://www.todosmedical.com/
https://investor.todosmedical.com/news-events...ement-with
MAY 26, 2020 9:19AM EDT
Todos gains distribution rights to LifeCan Ventilator in Brazil, Mexico & Latin America
Ventilator access will help prospective government and NGO procurers of COVID-related medical products reduce need for additional suppliers to address critical health needs
L1 distribution network will provide untapped market access for Todos’ tests
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a cross-distribution agreement with L1 Systems, Ltd., a wholly-owned subsidiary of Medigus, Ltd. (NASDAQ:MDGS) (TASE:MDGS), for the distribution of COVID-19 related products, including ventilators. Todos is making available to L1 its comprehensive suite of testing solutions that covers best-in-class RNA extraction equipment, RNA extraction reagents, qPCR reagents, Digital PCR reagents and US-validated SARS-CoV-2 rapid point-of-care antibody test kits for non-exclusive distribution. L1 is making available to Todos the LifeCan ventilators, manufactured by Elbit Systems, for non-exclusive distribution in Mexico and Latin America, including Brazil. This agreement strengthens both companies’ core offerings and allows each company to focus on markets where they are developing reliable sales channels.
“Given that Todos’ team has been focused recently on penetrating the Latin American market, where a marked uptick in COVID-19 infections has led to a significantly increased need for COVID-19 testing and critical care treatment options, we believe gaining access to a high quality medical grade ventilator will further bring attention to Todos’ test offering due to the severe global shortage in ventilators,” said Gerald Commissiong, President & CEO of Todos Medical.
Mr. Commissiong continued, “When a country is dealing with a pandemic crisis such as COVID-19, getting trusted sources of medical supplies from which a procurement agent can acquire multiple lines of needed products substantially increases a supplier’s profile within that procurement agency, and provides the supplier an opportunity to expose the procurer to the rest of its portfolio in a more comprehensive way. Ventilators are often the difference between life and death when treating patients, and we believe getting access to a nimble and tailored product such as LifeCan – a simple, high-quality product that was designed in Israel to respond to many of the recent concerns with the established medical ventilator designs – gives Todos a significant edge when competing for contracts from foreign governments, hospital systems and others users of healthcare products and services. As we continue to build our international import/export division, this agreement positions Todos to stand out from other companies competing for contracts in key markets.”
About the SARS-CoV-2 Coronavirus (COVID-19)
Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is the disease caused by SARS-CoV-2.
About Medigus, Ltd.
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the company’s advanced technology, please visit www.medigus.com.
About Todos Medical Ltd.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020.
Todos recently entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements with multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed Corona Diagnostics, LLC, a strategic collaboration with Emerald Organic Products, Inc. (OTC: EMOR), to support telemedicine and virtual pharmacy aspects of the commercialization of its COVID-19 return to work testing programs in the US.
For more information, please visit https://www.todosmedical.com/
https://investor.todosmedical.com/news-events...ement-with
2
